Aspoxicillin versus piperacillin in severe abdominal infections--a comparative phase III study

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Severe abdominal infections require effective antibiotic therapy.
• Broad-spectrum penicillin derivatives are crucial for managing polymicrobial infections.
• Comparing novel antibiotics with established treatments is essential for clinical practice.

Purpose of the Study:

• To compare the efficacy and safety of aspoxicillin with piperacillin in patients with severe abdominal infections.
• To evaluate aspoxicillin as a potential alternative to piperacillin for this patient population.

Main Methods:

• A randomized trial comparing aspoxicillin (4 g tds) with piperacillin (4 g qds) in patients with severe abdominal infections.
• Inclusion criteria: perforated appendicitis, acute cholecystitis, ulcer or colon perforation, or intra-abdominal abscess.
• Efficacy assessed by treatment response rates; cultures obtained for pathogen identification and susceptibility testing.

Main Results:

• Similar efficacy rates were observed: 90% treatment response for aspoxicillin (45/50) versus 91% for piperacillin (48/53).
• No statistically significant difference in efficacy between the two drugs (95% CI for difference: -12% to +11%).
• Both antibiotics were generally well-tolerated with no serious drug-related adverse events.

Conclusions:

• Aspoxicillin (4 g tds) is therapeutically equivalent to piperacillin (4 g qds) in treating severe abdominal infections.
• Aspoxicillin represents a viable treatment option for severe abdominal infections.
• Further research may explore aspoxicillin in other infection types.